What Bluefish Pharmaceuticals does

Bluefish Pharmaceuticals AB is a Swedish specialty generics pharmaceutical company founded in 2005 and headquartered in Stockholm. The company develops, manufactures (via partners), and markets off-patent generic medicines — bioequivalent to originator products — with a portfolio of 80+ commercialized products spanning seven or more therapeutic areas (CNS, cardiology, oncology, pain management, endocrinology, urology, and antibiotics) and four or more formulation types (ointments, eye drops, capsules, and tablets). Bluefish is a privately held subsidiary of Färna Invest AB, which owns 92.68% of shares, and it operates commercially across 13 European countries through wholly-owned local entities in Austria, France, Germany, Ireland, Poland, Portugal, Spain, and Sweden.

The company's core technology is in-house generic formulation development, anchored by its Global Technology & Development Centre in Bangalore, India, staffed with experts in formulation, analytical development, clinical evaluation, intellectual property, and quality assurance. Bluefish pursues non-infringing formulations of off-patent reference products, with development timelines averaging 18–24 months, and supplements internal capacity with Contract Development Organisations and global manufacturing partners selected for project-specific expertise. The company is authorized by the Swedish Medical Products Agency (Läkemedelsverket) and operates under cGMP, GDP, and GVP compliance frameworks.

Bluefish runs a sales-led go-to-market targeting pharmacies, wholesalers, and governmental and private healthcare institutions across Europe, with country-specific product and marketing strategies. Revenue is generated primarily through one-time sales of generic pharmaceutical products (MSEK 484.80 in FY 2023/2024, ~49.6% gross margin), supplemented by partnering services including contract formulation development, product in-licensing, distribution agreements, and proprietary product out-licensing. Pricing is set via B2B contracts rather than public lists. As of October 2025, Christian Paulsson serves as CEO following the departure of Annika Muskantor.

Name

Bluefish Pharmaceuticals

Legal name

Bluefish Pharmaceuticals AB

Website

https://bluefishpharma.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Bluefish Pharmaceuticals AB is a Swedish specialty generics company developing and selling 80+ off-patent medicines across 13 European countries, serving pharmacies, wholesalers, and governmental and private healthcare institutions.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Generic pharmaceuticals
• Generic drug development
• Pharmaceutical formulation
• Off-patent medicines
• Pharmaceutical distribution Europe

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: Revenue generated from development and sale of generic pharmaceutical products across 13 European countries. Products are sold to pharmacies, wholesalers, and governmental/private healthcare institutions. The portfolio includes approximately 80 commercialized products plus products in various stages of development.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

Bluefish Pharmaceuticals develops and sells affordable, high-quality generic pharmaceutical products that are bioequivalent to originator medicines. Its portfolio covers more than 80 products across therapeutic areas including CNS, cardiology, oncology, pain control, endocrinology, urology, and antibiotics, in formulations such as ointments, eye drops, capsules, and tablets. The company also offers in-house formulation development, product in-licensing and out-licensing, and distribution partnerships across 13 European countries.

Product overview

Bluefish Pharmaceuticals operates as a fully integrated pharmaceutical organization offering a unified platform of generic pharmaceutical products and development services. The core product is a portfolio of over 80 generic pharmaceutical products spanning 7+ therapeutic areas (CNS, cardiology, oncology, pain control, endocrinology, urology, antibiotics) and 4+ formulation types (ointments, eye drops, capsules, tablets). These are complemented by product development services including in-house formulation development (with a technical center in Bangalore, India), contract formulation development, product in-licensing, distribution agreements, and proprietary product out-licensing. The company functions as a vertically integrated organization covering the full pharmaceutical value chain from development through commercialization, with manufacturing operations supported by global manufacturing partners and distribution through European pharmacies, wholesalers, and institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Products Portfolio Core portfolio of generic pharmaceutical products derived from well-established generic substances, bioequivalent to originator products, spanning therapeutic areas including CNS, cardiology, oncology, pain control, endocrinology, urology, and antibiotics. The portfolio comprises over 80 products available in formulations such as ointments, eye drops, capsules, and tablets, sold to pharmacies, wholesalers, and governmental and private healthcare institutions.
• Product Development Services In-house product formulation development services that develop generic versions of reference products using innovative formulation approaches, ensuring non-infringing products that meet safety, efficacy, and quality requirements. Development is performed at the Bangalore technology centre, with a typical 18-24 month timeline, granting Bluefish ownership of resulting formulations.
• Formulation Development (Partnering) Contract formulation development services offered as part of Bluefish's partnering program, focused on developing niche, complex, or strategically significant generic pharmaceutical formulations in collaboration with partners.
• Product In-licensing Strategic product in-licensing arrangements where Bluefish acquires rights to manufacture and market generic pharmaceutical products from other developers as part of its partnering program.
• Distribution Agreements Distribution partnership arrangements enabling Bluefish to distribute generic pharmaceutical products across European markets through pharmacies, wholesalers, and governmental and private institutions as part of its partnering program.
• Proprietary Product Out-licensing Out-licensing of proprietary products developed by Bluefish, granting other parties rights to manufacture or market Bluefish-developed generic pharmaceuticals in specified territories as part of its partnering program.

Quantifiable outcome

• 49.6% gross margin in FY 2023/2024
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Development and Manufacturing PartnerscoreStrategic or Co-development PartnerBluefish partners with development and manufacturing experts to ensure each product meets rigorous quality standards. These strategic alliances are primarily centred around product sourcing and manufacturing, with expertise extending to development, regulatory approvals, go-to-market strategies, and marketing initiatives.
• Contract Development Organisations (CDOs)coreStrategic or Co-development PartnerBluefish maintains close collaboration with CDOs, selecting partners with specific expertise and experience tailored to each project's requirements. These partnerships ensure seamless project execution for product development.
• Shanti Bhavan SchoolminorOthersBluefish supports education for underprivileged children in India through sponsorship of Shanti Bhavan School, a corporate social responsibility initiative. This partnership contributes to positive change for individuals and families in the Indian community where Bluefish operates its development centre.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with broad European presence across therapeutic areas and dosage forms. Directly comparable to Bluefish in off-patent small-molecule generics targeting pharmacies, wholesalers and institutions, but at vastly greater scale and geographic reach.
• Sandoz: Novartis-spin-off global generics and biosimilars leader with deep European footprint. Competes head-to-head with Bluefish in off-patent small molecules across multiple therapeutic categories and dosage forms sold through retail pharmacies and institutional channels.
• Viatris: Major global generics player formed via Mylan-Upjohn combination with significant European generics portfolio. Highly comparable to Bluefish on multi-country European distribution, off-patent focus, and institutional/retail pharmacy channel mix.
• Aurobindo Pharma: Indian-headquartered global generics manufacturer with large European operations. Comparable to Bluefish as a low-cost generics supplier with European footprint; relevant especially given Bluefish's Bangalore-based R&D centre and partnership-driven manufacturing model.

Direct peers

• Stada Arzneimittel: German-headquartered European generics specialist with similar country footprint, off-patent focus and pharmacy/wholesaler channel strategy. Closely comparable on business model, therapeutic breadth and target customer base.
• Zentiva: European-focused generics company headquartered in Prague serving pharmacies, wholesalers and institutions across multiple EU markets. Highly comparable on geographic concentration, therapeutic breadth and product portfolio scale relative to Bluefish.
• Krka: Slovenian-headquartered European generics manufacturer with strong pharmacy/wholesaler channels across Central and Eastern Europe. Comparable on model of vertical integration from API through finished dosage forms and multi-country European distribution.

Emerging players

• Alvotech: Icelandic-founded specialty generics and biosimilars developer with European commercial presence. Overlaps with Bluefish in the development of complex, hard-to-make off-patent products using proprietary formulation technology, though focused on biologics.
• Polpharma Biologics: Polish-headquartered generics and biosimilars developer operating across European markets. Comparable on Central European footprint, focus on differentiated generics and pharmacy/wholesaler channel mix.

Regional players

• Apotex: Canadian-headquartered generics manufacturer with growing European presence. Comparable business model of in-house development plus contract manufacturing for off-patent small molecules sold into retail and institutional channels.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bluefish-pharmaceuticals-group

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluefish Pharmaceuticals